Patient dies following muscular dystrophy gene therapy, Sarepta reports
Advertisement
Read this article for free:
or
Already have an account? Log in here »
To continue reading, please subscribe:
Digital Subscription
One year of digital access for only $205*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*First annual payment billed as $205.00 + GST for one year. This annual subscription will automatically renew at $233.00 + GST every 52 weeks (10% off the regular annual price of $259.35). Offer available to new and qualified returning subscribers only. Cancel any time.
To continue reading, please subscribe:
Add Free Press access to your Brandon Sun subscription for only an additional
$1 for the first 4 weeks*
- Enjoy unlimited reading on winnipegfreepress.com
- Read the E-Edition, our digital replica newspaper
- Access News Break, our award-winning app
- Play interactive puzzles
*Your next Brandon Sun subscription payment will increase by $1.00 and you will be charged $17.95 plus GST for four weeks. After four weeks, your payment will increase to $24.95 plus GST every four weeks.
Read unlimited articles for free today:
or
Already have an account? Log in here »
Hey there, time traveller!
This article was published 18/03/2025 (549 days ago), so information in it may no longer be current.
WASHINGTON (AP) — Sarepta Therapeutics said Tuesday that a patient died while taking its closely watched gene therapy for muscular dystrophy, sending company shares plummeting more than 25%.
The young man died of acute liver injury, a known side effect, Sarepta said in a statement. But the company said the “severity” of the patient’s case had not previously been seen with the therapy, called Elevidys. It’s the first known patient death with the therapy, which has been used in more than 800 patients, the company said.
In 2023, Elevidys received expedited U.S. approval despite concerns from some Food and Drug Administration scientists about its effectiveness in treating Duchenne muscular dystrophy. It’s the first gene therapy approved in the U.S. for the rare muscle-wasting condition, which causes weakness, loss of mobility and early death in males.
The FDA granted full approval last year for Duchenne’s patients with a particular genetic mutation, expanding its use to patients 4 and older, regardless of whether they are still able to walk. Previously it was only available for younger patients who were still mobile.
Sarepta said in a statement the patient who died had a recent infection that could have contributed to the liver injury. The company said it plans to update the prescribing information for Elevidys to reflect the case.
Shares of the Cambridge, Massachusetts-based company fell more than 27% Tuesday to close at about $73 each.
Elevidys uses a disabled virus to insert a replacement gene for producing dystrophin into patient cells. It costs $3.2 million for a one-time infusion.
Sarepta has received FDA accelerated approval for three
other Duchenne’s drugs since 2016. None has yet been confirmed to work; studies designed to secure full FDA approval are ongoing.
___
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
